Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy

References

• Zheng R, Zeng H, Zuo T, Zhang S, Qiao Y, Zhou Q, Chen W. Lung cancer incidence and mortality in China, 2011. Thoracic cancer 2016; 7:94-9; PMID:26816543; https://doi.org/10.1111/1759-7714.12286
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66:115-32; PMID:26808342; https://doi.org/10.3322/caac.21338
   Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; https://doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Abratt RP, Hart GJ. 10-year update on chemotherapy for non-small cell lung cancer. Ann Oncol 2006; 17 Suppl 5:v33-6; PMID:16807460; https://doi.org/10.1093/annonc/mdj947
   Google Scholar
• Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, et al. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Cancer Netw 2015; 13:515-24; PMID:25964637
   PubMed Web of Science ®Google Scholar
• Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR, et al. A unified model for apical caspase activation. Mol Cell 2003; 11:529-41; PMID:12620239; https://doi.org/10.1016/S1097-2765(03)00051-0
   PubMed Web of Science ®Google Scholar
• Fiandalo MV, Schwarze SR, Kyprianou N. Proteasomal regulation of caspase-8 in cancer cell apoptosis. Apoptosis 2013; 18:766-76; PMID:23456622; https://doi.org/10.1007/s10495-013-0821-y
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12:611-20; PMID:10894161; https://doi.org/10.1016/S1074-7613(00)80212-5
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Ghosh MK. Cell death and deubiquitinases: perspectives in cancer. Bio Med Res Int 2014; 2014:435197. PMID:25121098; https://doi.org/10.1155/2014/435197
   PubMedGoogle Scholar
• McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 2013; 5:a008656. PMID:23545416; https://doi.org/10.1101/cshperspect.a008656
   PubMed Web of Science ®Google Scholar
• Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001; 2:930-42; PMID:11733746; https://doi.org/10.1038/35103535
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee JW, Soung YH, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Jeong SW, et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 2003; 125:708-15; PMID:12949717; https://doi.org/10.1016/S0016-5085(03)01059-X
   PubMed Web of Science ®Google Scholar
• Soung YH, Lee JW, Kim SY, Jang J, Park YG, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 2005; 65:815-21; PMID:15705878
   PubMed Web of Science ®Google Scholar
• Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, et al. A 6-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007; 39:605-13; PMID:17450141; https://doi.org/10.1038/ng2030
   PubMed Web of Science ®Google Scholar
• Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, Penegar S, Tomlinson I, Houlston RS. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer 2008; 98:1434-6; PMID:18362937; https://doi.org/10.1038/sj.bjc.6604314
   PubMed Web of Science ®Google Scholar
• MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, Ponder BA, Meuth M, Bhattacharyya NP, Cox A. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Institute 2004; 96:1866-9; PMID:15601643; https://doi.org/10.1093/jnci/dji001
   PubMedGoogle Scholar
• Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007; 39:352-8; PMID:17293864; https://doi.org/10.1038/ng1981
   PubMed Web of Science ®Google Scholar
• Qian J, Qu HQ, Yang L, Yin M, Wang Q, Gu S, Wu Q, Zhao X, Wu W, Wu J, et al. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Oncologist 2012; 17:1551-61; PMID:22843554; https://doi.org/10.1634/theoncologist.2011-0419
   PubMed Web of Science ®Google Scholar
• Chang DW, Xing Z, Capacio VL, Peter ME, Yang X. Interdimer processing mechanism of procaspase-8 activation. EMBO J 2003; 22:4132-42; PMID:12912912; https://doi.org/10.1093/emboj/cdg414
   PubMed Web of Science ®Google Scholar
• Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10:348-55; PMID:19295631; https://doi.org/10.1038/ni.1714
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011; 471:373-6; PMID:21368761; https://doi.org/10.1038/nature09878
   PubMed Web of Science ®Google Scholar
• Oberst A, Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat Rev Mol Cell Biol 2011; 12:757-63; PMID:22016059; https://doi.org/10.1038/nrm3214
   PubMed Web of Science ®Google Scholar
• Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van der Zee AG, de Vries EG, de Jong S. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer 2011; 104:1278-87; PMID:21487429; https://doi.org/10.1038/bjc.2011.84
   PubMed Web of Science ®Google Scholar
• Van Geelen CM, Pennarun B, Ek WB, Le PT, Spierings DC, De Vries EG, De Jong S. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol 2010; 37:1031-41; PMID:20811726; https://doi.org/10.3892/ijo_00000755
   PubMed Web of Science ®Google Scholar
• Wu H, Meng S, Xu Q, Wang X, Wang J, Gong R, Song Y, Duan Y, Zhang Y. Gene expression profiling of lung adenocarcinoma in Xuanwei, China. Eur J Cancer Prev 2015; 25(6):508-17; PMID:26695082; https://doi.org/10.1097/CEJ.0000000000000214
   Web of Science ®Google Scholar
• Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, et al. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer 2015; 122:766-72; PMID:26695526; https://doi.org/10.1002/cncr.29812.
   Web of Science ®Google Scholar
• Catana A, Pop M, Hincu BD, Pop IV, Petrisor FM, Porojan MD, Popp RA. The XRCC1 Arg194Trp polymorphism is significantly associated with lung adenocarcinoma: a case-control study in an Eastern European Caucasian group. OncoTargets Ther 2015; 8:3533-8; PMID:26664136; https://doi.org/10.2147/OTT.S92361
   PubMed Web of Science ®Google Scholar
• Somasundaram A, Socinski MA, Burns TF. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Exp Opin Pharmacother 2014; 15:2693-708; PMID:25381900; https://doi.org/10.1517/14656566.2014.971013
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama 2014; 311:1998-2006; PMID:24846037; https://doi.org/10.1001/jama.2014.3741
   PubMed Web of Science ®Google Scholar
• Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-91; PMID:12114432
   PubMed Web of Science ®Google Scholar
• Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res 2013; 5:327-36; PMID:24124391; https://doi.org/10.2147/CMAR.S52073
   PubMedGoogle Scholar
• Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-8; PMID:17314339; https://doi.org/10.1056/NEJMoa065411
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91; PMID:16957145; https://doi.org/10.1056/NEJMoa060570
   PubMed Web of Science ®Google Scholar
• Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW. Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands) 2012; 77:9-15; PMID:22306125; https://doi.org/10.1016/j.lungcan.2012.01.005
   PubMed Web of Science ®Google Scholar
• Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M, et al. Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PloS one 2013; 8:e71356. PMID:23940741; https://doi.org/10.1371/journal.pone.0071356
   PubMed Web of Science ®Google Scholar
• Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2013; 31:2404-12; PMID:23690416; https://doi.org/10.1200/JCO.2012.46.9783
   PubMed Web of Science ®Google Scholar
• Liu D, Wu C, Jiao Y, Hou L, Lu D, Zheng H, Chen C, Qian J, Fei K, Su B. WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients. Scientific Rep 2015; 5:11114. PMID:26057002; https://doi.org/10.1038/srep11114
   PubMed Web of Science ®Google Scholar
• Son JW, Kang HK, Chae MH, Choi JE, Park JM, Lee WK, Kim CH, Kim DS, Kam S, Kang YM, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet cytogenetics 2006; 169:121-7; PMID:16938569; https://doi.org/10.1016/j.cancergencyto.2006.04.001
   PubMedGoogle Scholar
• Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2011; 71:123-9; PMID:20471133; https://doi.org/10.1016/j.lungcan.2010.04.016
   PubMed Web of Science ®Google Scholar
• Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, et al. CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients. PloS one 2014; 9:e114696. PMID:25502557; https://doi.org/10.1371/journal.pone.0114696
   PubMed Web of Science ®Google Scholar
• Hattinger CM, Serra M. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma. Exp Opin Drug Metab Toxicol 2015; 11:1449-63; PMID:26095223; https://doi.org/10.1517/17425255.2015.1060220
   PubMed Web of Science ®Google Scholar
• Phillips FC, Gurung P, Kanneganti TD. Microbiota and caspase-1/caspase-8 regulate IL-1beta-mediated bone disease. Gut Microbes 2016; 7:1-8; PMID:27148834; https://doi.org/10.1080/19490976.2016.1182289
   PubMedGoogle Scholar
• Gurung P, Anand PK, Malireddi RK, Vande Walle L, Van Opdenbosch N, Dillon CP, Weinlich R, Green DR, Lamkanfi M, Kanneganti TD. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J Immunol 2014; 192:1835-46; PMID:24453255; https://doi.org/10.4049/jimmunol.1302839
   PubMed Web of Science ®Google Scholar
• Gurung P, Li B, Subbarao Malireddi RK, Lamkanfi M, Geiger TL, Kanneganti TD. Chronic TLR Stimulation Controls NLRP3 Inflammasome Activation through IL-10 Mediated Regulation of NLRP3 Expression and Caspase-8 Activation. Sci Rep 2015; 5:14488. PMID:26412089; https://doi.org/10.1038/srep14488
   PubMed Web of Science ®Google Scholar
• Camp NJ, Lin WY, Bigelow A, Burghel GJ, Mosbruger TL, Parry MA, Waller RG, Rigas SH, Tai PY, Berrett K, et al. Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Res 2016; 76:1916-25; PMID:26795348; https://doi.org/10.1158/0008-5472.CAN-15-1629
   PubMed Web of Science ®Google Scholar
• Lan Q, Morton LM, Armstrong B, Hartge P, Menashe I, Zheng T, Purdue MP, Cerhan JR, Zhang Y, Grulich A, et al. Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood 2009; 114:264-7; PMID:19414860; https://doi.org/10.1182/blood-2009-01-198697
   PubMedGoogle Scholar
• Zhang YJ, Zhong XP, Chen Y, Liu SR, Wu G, Liu YF. Association between CASP-8 gene polymorphisms and cancer risk in some Asian population based on a HuGE review and meta-analysis. Genet Mol Res 2013; 12:6466-76; PMID:23479148; https://doi.org/10.4238/2013.February.28.3
   PubMedGoogle Scholar
• George GP, Mandal RK, Kesarwani P, Sankhwar SN, Mandhani A, Mittal RD. Polymorphisms and haplotypes in caspases 8 and 9 genes and risk for prostate cancer: a case-control study in cohort of North India. Urologic Oncol 2012; 30:781-9; PMID:21396853; https://doi.org/10.1016/j.urolonc.2010.08.027
   PubMed Web of Science ®Google Scholar